Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of “Hold” by Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus recommendation of “Hold” from the seventeen brokerages that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $44.5385.

A number of brokerages recently commented on HIMS. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. UBS Group set a $32.00 price objective on Hims & Hers Health in a research note on Tuesday, November 4th. KeyCorp assumed coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Finally, BTIG Research restated a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th.

Insider Activity at Hims & Hers Health

In other news, insider Deborah M. Autor sold 7,054 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the transaction, the insider directly owned 6,175 shares in the company, valued at $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Chi sold 13,750 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 131,974 shares of company stock worth $4,763,800 in the last 90 days. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. MOKAN Wealth Management Inc. grew its holdings in Hims & Hers Health by 69.4% during the 4th quarter. MOKAN Wealth Management Inc. now owns 6,488 shares of the company’s stock valued at $211,000 after buying an additional 2,657 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Hims & Hers Health by 5.5% during the fourth quarter. Farther Finance Advisors LLC now owns 20,057 shares of the company’s stock worth $651,000 after acquiring an additional 1,052 shares during the last quarter. Cura Wealth Advisors LLC grew its stake in Hims & Hers Health by 8.5% during the fourth quarter. Cura Wealth Advisors LLC now owns 6,512 shares of the company’s stock valued at $211,000 after acquiring an additional 512 shares in the last quarter. State of Alaska Department of Revenue increased its holdings in Hims & Hers Health by 63.6% in the 4th quarter. State of Alaska Department of Revenue now owns 37,029 shares of the company’s stock valued at $1,202,000 after acquiring an additional 14,396 shares during the last quarter. Finally, Diligent Investors LLC increased its holdings in Hims & Hers Health by 5.1% in the 4th quarter. Diligent Investors LLC now owns 13,198 shares of the company’s stock valued at $429,000 after acquiring an additional 640 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $30.31 on Tuesday. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The stock has a market capitalization of $6.90 billion, a PE ratio of 56.13, a price-to-earnings-growth ratio of 4.88 and a beta of 2.37. The firm’s 50 day moving average price is $34.84 and its 200-day moving average price is $44.87. Hims & Hers Health has a twelve month low of $23.97 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same quarter last year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has approved a stock buyback plan on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.